Lobe Sciences Ltd.
LOBEF
$0.04
$0.000.00%
OTC PK
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -27.43% | 287.66% | 95.44% | 7.93% | 34.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 122.43% | 188.77% | 186.09% | 1.84% | -7.33% |
| Operating Income | -122.43% | -188.77% | -186.09% | -1.84% | -15.58% |
| Income Before Tax | -60.72% | 20.66% | -157.69% | -10.85% | -39.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -60.72% | 21.58% | -157.69% | -10.85% | -39.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.75% | 31.59% | -123.53% | -10.85% | -39.90% |
| EBIT | -122.43% | -188.77% | -186.09% | -1.84% | -15.58% |
| EBITDA | -- | -185.44% | -204.40% | -3.43% | -17.80% |
| EPS Basic | 26.47% | -323.23% | -33.33% | 53.57% | 35.85% |
| Normalized Basic EPS | 47.62% | -1,456.31% | -23.53% | 45.71% | 36.36% |
| EPS Diluted | 26.47% | -323.23% | -33.33% | 53.57% | 35.85% |
| Normalized Diluted EPS | 47.62% | -1,456.31% | -23.53% | 45.71% | 36.36% |
| Average Basic Shares Outstanding | 53.83% | -83.83% | 68.66% | 135.50% | 119.50% |
| Average Diluted Shares Outstanding | 53.83% | -83.83% | 68.66% | 135.50% | 119.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |